Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The XIII International AIDS Conference
Hepatitis C and HIV Co-infection: Clinical Aspects

July 13, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • Effect of HIV infection on hepatitis C virus (HCV) infection in hemophiliacs and I.V. drug users (ThOrB654)
    Authored by J.K. Rockstroh, O. Loch, B. Helm, O. Degen, H. Brockmeyer, R. Kaiser (Germany)
  • The influence of hepatitis C virus (HCV) on the prognosis of HIV-infected persons: The EuroSIDA study (ThOrB655)
    Authored by V. Soriano, O. Kirk, F. Antunes, M. Johnson, A. d'Arminio Monforte, L.S. Teglbjorg, F.-D. Goebel, J.D. Lundgren (Italy)
  • Long-term efficacy and safety of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients. (ThOrB656)
    Authored by A. Landau, D. Batisse, C. Piketty, J.P. Duong Van Huyen, F. Bloch, G. Pialoux, L. Belec, R. Jian, L. Weiss, M.D. Kazatchkine (France)
  • Hepatitis C in HIV-infected patients in Russia (ThOrB658)
    Authored by A. Kravtchenko, V.G. Kanestri, O.Y.U. Shipulina, O.A. Tishkevich, I.A. Simonova (Russia)
  • Treatment of hepatitis C with recombinant alpha 2a interferon (RIFNA2A) in HIV seropositives in the HAART era (ThOrB659)
    Authored by S. Zaltron, G. Carosi, M. Puoti, S. Zaltron, B. Zanini, V. Putzolu, P. Delle Foglie, P. Quinzan, P. Costa, R. Marino, M. Andreoni, G. Stagni (Italy)


Thursday afternoon brought me to an oral session of papers on hepatitis C (HCV) and HIV co-infection (CoInf). We have seen a burgeoning interest and concern about hepatitis C in people with HIV infection. HCV progresses rapidly when associated with advanced HIV disease. We have only just recently begun systematic study of the interrelationships of these two infections. Very few studies have yet to be performed with treatment interventions for HCV in CoInf. I have seen reluctance on the part of physicians to prescribe therapy (i.e., interferon and ribavirin) for HCV until more data on the short- and long-term outcomes and adverse effects of these therapies are available.


Effect of HIV infection on hepatitis C virus (HCV) infection in hemophiliacs and I.V. drug users (ThOrB654)

Dr. Rockstroh, from Germany, described a cohort of hemophiliacs and IDUs with CoInf. CD4 was higher in the IDUs, but otherwise both groups were similar with respect to CD4, HIV viral load, HCV viral load, and liver function tests. The genotype strain of HCV can be correlated with either an improved or worsened prognosis (from liver disease). The hemophiliac co-infected patients tended to have both favorable and unfavorable genotypes; the IDUs tended to have unfavorable genotypes.


The influence of hepatitis C virus (HCV) on the prognosis of HIV-infected persons: The EuroSIDA study (ThOrB655)

This study investigated the effect of HCV infection on HIV in CoInf patients. He looked at the EuroSIDA cohort PK over 8,500 HIV patients. Of these, 4,078 had HCV antibody testing; 33% were HCV-positive. Compared to those who were HCV-negative, the HCV-positive were more likely to be female, caucasian, younger, and less likely to have an AIDS diagnosis. During the follow-up period that averaged almost three years a higher percentage (16%) of those with CoInf died compared to those with HIV infection alone (12%). The risk of death was analyzed statistically and found to be associated with CoInf, increased age, lower CD4 counts and a baseline AIDS diagnosis.


Long term efficacy and safety of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients. (ThOrB656)

A study that looked at combination therapy with IFN and RBV was presented during the this session by Landau from France. Sixty-six CoInf patients were treated with IFN (3 million units three times weekly) and oral RBV for six months in patients whose liver biopsies showed mild fibrosis and for 12 months in patients whose biopsies showed (or worse) fibrosis. All patients had pre-treatment liver biopsies. 57% of patients had genotype 1a or 1b, HCV viral loads were high, cirrhosis was common (42%). Overall only 24% of patients showed a sustained virologic response six months after completing therapy. The genotype 3a pts did better as expected, with 63% having a sustained response. Adverse effects were common leading to 23% discontinuing treatment and others reducing dosages of IFN or RBV or both.


Hepatitis C in HIV-infected patients in Russia (ThOrB658)

Dr. Kravtchenko described the state of HCV/HIV coinfection in the Moscow region of Russia. He reported on an "exploding" epidemic of CoInf with approximately 90% of IDUs in that region having CoInf. The 3a genotype, which is generally associated with a favorable prognosis, occurred in 60%. Twenty-nine of their patients underwent liver biopsy revealing mild-moderate findings of fibrosis. He also reported on very preliminary data from a treatment trial using interferon and rimantidine (this is not the same as ribavirin).


Treatment of hepatitis C with recombinant alpha 2a interferon (RIFNA2A) in HIV seropositives in the HAART era (ThOrB659)

Dr. Zaltron, et al., from Italy, discussed treatment of HCV in CoInf patients using interferon therapy alone (no ribavirin) or no therapy. In a group of 83 CoInf patients the early results, at the end of three months of therapy, were poor (only 34% suppressed HCV viremia) and not sustained after treatment was discontinued. The IFN treatment did not have serious adverse effects nor did it cause any significant change in CD4 counts or HIV viral load. We already know from studies in HCV-infected (without HIV) patients that IFN monotherapy does not work well, and does not work as well as combination therapy with ribavirin.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More Hepatitis C Research



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement